Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo

Journal of Cachexia, Sarcopenia and Muscle

Volumn 7, Issue 4, 2016, Pages 436-448

  Patel, Mehul S ^a   Lee, Jen ^b   Baz, Manuel ^a   Wells, Claire E ^c   Bloch, Susannah ^a   Lewis, Amy ^b   Donaldson, Anna V ^a   Garfield, Benjamin E ^a   Hopkinson, Nicholas S ^a   Natanek, Amanda ^a   Man, William D C ^a   Wells, Dominic J ^d   Baker, Emma H ^c   Polkey, Michael I ^a   Kemp, Paul R ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Atrophy; COPD; Electroporation; GDF 15; Muscle mass

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; EXERCISE; FEMALE; GENE EXPRESSION; HUMAN; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RECTUS FEMORIS MUSCLE; TIBIALIS ANTERIOR MUSCLE;

EID: 84952683994     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12096     Document Type: Article

References (39)

1. Man WD, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin Sci (Lond) 2009;117:251–264.
2. Patel MS, Natanek SA, Stratakos G, Pascual S, Martinez-Llorens J, Disano L, et al. Vastus lateralis fiber shift is an independent predictor of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;190:350–352.
3. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;62:115–120.
4. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 2010;33:1567–1572.
5. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wilkins MR. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011;97:1054–1060.
6. Nickel N, Jonigk D, Kempf T, Bockmeyer CL, Maegel L, Rische J, et al. GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respir Res 2011;12.
7. Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak AG, Roden M, et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol/Eur Fed Endoc Soc 2010;162:913–917.
8. Kempf T, Wollert KC. Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. Crit Care 2013;17:173, doi:10.1186/cc12765.
9. Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013;59:1091–1098.
10. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010;9:1057–1064.
11. Bloch S, Lee JY, Wort SJ, Polkey MI, Kemp P, Griffiths M. Sustained elevation of circulating GDF-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. Crit Care Med 2013;41:982–989.
12. Tsai VW, Husaini Y, Manandhar R, Lee-Ng KK, Zhang HP, Harriott K, et al. Anorexia/cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1/GDF15. J Cachexia Sarcopenia Muscle 2012;3:239–243.
13. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21:4212–4219, doi:10.1038/sj.onc.1205610.
14. Dandrea T, Hellmold H, Jonsson C, Zhivotovsky B, Hofer T, Warngard L, et al. The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation. Free Radic Biol Med 2004;36:881–896.
15. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94:11514–11519.
16. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
17. Patel MS, Donaldson AV, Lewis A, Natanek Samantha A, Shrikrishna D, Martolini D, et al. Serum and quadriceps expression of klotho in smokers and COPD patients. Am Thoracic Soc 2013;187:A6018-A.
18. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
19. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–735.
20. Boutou AK, Shrikrishna D, Tanner RJ, Smith C, Kelly JL, Ward SP, et al. Lung function indices for predicting mortality in COPD. Eur Respir J 2013;42:616–625.
21. Mahler D. C. W. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580–586.
22. Brown CD, Wise RA. Field tests of exercise in COPD: the six-minute walk test and the shuttle walk test. COPD 2007;4:217–223.
23. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011;105:57–66.
24. Steiner MC, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 2002;19:626–631.
25. Swallow EB, Gosker HR, Ward KA, Moore AJ, Dayer MJ, Hopkinson NS, et al. A novel technique for nonvolitional assessment of quadriceps muscle endurance in humans. J Appl Physiol 2007;103:739–746.
26. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012;40:1115–1122.
27. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax 2012;67:26–34.
28. Ellis PD, Smith CW, Kemp P. Regulated ?>tissue-specific alternative splicing of enhanced green fluorescent protein transgenes conferred by alpha-tropomyosin regulatory elements in transgenic mice. J Biol Chem 2004;279:36660–36669.
29. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle b y pretreatment with hyaluronidase—increased expression with reduced muscle damage. Gene Ther 2001;8:1264–1270.
30. Gollins H, McMahon J, Wells KE, Wells DJ. High-efficiency plasmid gene transfer into dystrophic muscle. Gene Ther 2003;10:504–512.
31. Martin KM, Cooper WN, Metcalfe JC, Kemp PR. Mouse BTEB3, a new member of the basic transcription element binding protein (BTEB) family, activates expression from GC-rich minimal promoter regions. Biochem J 2000;345:529–533.
32. Favot L, Hall SM, Haworth SG, Kemp PR. Cytoplasmic YY1 is associated with increased smooth muscle-specific gene expression: implications for neonatal pulmonary hypertension. Am J Pathol 2005;167:1497–1509.
33. Diaz AA, Morales A, Diaz JC, Ramos C, Klaassen J, Saldias F, et al. CT and physiologic determinants of dyspnea and exercise capacity during the six-minute walk test in mild COPD. Respir Med 2013;107:570–579.
34. Andrianopoulos V, Wagers SS, Groenen MT, Vanfleteren LE, Franssen FM, Smeenk FW, et al. Characteristics and determinants of endurance cycle ergometry and six-minute walk distance in patients with COPD. BMC Pulm Med 2014;14:97, doi:10.1186/1471-2466-14-97.
35. Natanek SA, Gosker HR, Slot IG, Marsh GS, Hopkinson NS, Man WD-C, et al. Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (COPD); implications for stratified medicine? Muscle and Nerve 2013;48:488–497.
36. Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN, et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 2009;69:652–661.
37. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410–3415.
38. Natanek SA, Gosker H, Slot I, Marsh G, Hopkinson NS, Moxham J, et al. Pathways associated with reduced quadriceps oxidative fibre proportion in COPD. Eur Resp J 2013;41:1275–1283.
39. Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR et al. Increased expression of GDF-15 may mediate ICU acquired weakness by down-regulating muscle microRNAs. Thorax. 2014: available online at doi:10.1136/thoraxjnl-2014-206225.